Cardiff Oncology Inc CRDF.OQ CRDF.O is expected to show a fall in quarterly revenue when it reports results on November 5 (estimated) for the period ending September 30 2025
The San Diego California-based company is expected to report a 31.8% decrease in revenue to $112.5 thousand from $165 thousand a year ago, according to the mean estimate from 8 analysts, based on LSEG data.
LSEG's mean analyst estimate for Cardiff Oncology Inc is for a loss of 20 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Cardiff Oncology Inc is $10.00, about 76.5% above its last closing price of $2.35
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -0.19 | -0.19 | -0.21 | Missed | -9.1 |
Mar. 31 2025 | -0.18 | -0.19 | -0.20 | Missed | -7.4 |
Dec. 31 2024 | -0.23 | -0.24 | -0.22 | Beat | 9 |
Sep. 30 2024 | -0.27 | -0.27 | -0.25 | Beat | 7.4 |
Jun. 30 2024 | -0.25 | -0.26 | Missed | -5.1 | |
Mar. 31 2024 | -0.25 | -0.25 | -0.22 | Beat | 11.1 |
Dec. 31 2023 | -0.27 | -0.28 | -0.21 | Beat | 24.3 |
Sep. 30 2023 | -0.28 | -0.28 | -0.22 | Beat | 22.8 |
This summary was machine generated November 3 at 21:48 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments